TLDR: Pune-based Medvolt AI is revolutionizing drug discovery by integrating generative AI, graph AI, natural language processing, and physics-based simulations. This innovative platform aims to drastically cut preclinical development timelines, reduce R&D expenditures, and mitigate failure risks, thereby making drug development significantly faster, more affordable, and more efficient.
Medvolt AI, a pioneering startup based in Pune, is at the forefront of transforming the traditionally slow, expensive, and uncertain landscape of pharmaceutical research and development. The company leverages advanced artificial intelligence (AI), specifically generative AI, in conjunction with graph AI, natural language processing (NLP), and physics-based simulations, to accelerate and streamline drug discovery processes.
The pharmaceutical industry has long grappled with drug development cycles that can span over a decade and incur costs running into billions of dollars, with a high percentage of candidates failing before reaching human trials. The most significant bottlenecks often occur in the preclinical stage, where scientists spend years identifying, testing, and refining molecular compounds. Medvolt AI addresses this challenge by offering an end-to-end preclinical drug discovery platform designed to inject speed, precision, and cost-efficiency into this critical phase.
Founded in 2022, though registered in 2020, Medvolt AI is the brainchild of Dr. Madhura Vipra, a life sciences veteran with over three decades of experience who serves as the CEO, and her son, Ritvik Vipra, the Co-founder and CTO. Ritvik, an IIT Roorkee alumnus and machine learning engineer, developed a strong foundation in data science and AI through his previous roles at Athena and YOUPLUS. The inspiration for Medvolt AI arose when Ritvik assisted his mother in automating aspects of her biomedical consulting workflows, revealing the immense potential of combining deep domain expertise in biology and chemistry with cutting-edge AI technologies to dramatically shorten research timelines.
Medvolt AI’s proprietary ‘MedGraph’ platform is central to its offerings. This platform utilizes generative AI to design novel drug molecules, graph AI for complex data relationships, NLP for high-throughput data curation, and physics-based modeling for accurate simulations. Key components of the platform include MedGraph™ – Topaaz for de novo drug design and hit-to-lead optimization (Medkush), MedGraph™ – Rubie for drug repurposing, and MedGraph™ – Oopal – FEP for predicting binding affinity changes. According to Ritvik Vipra, “Our goal is to make drug development faster, cheaper, and more efficient. AI and domain expertise together help researchers take more shots on goal.”
The company asserts that its AI-powered platform can reduce project timelines by up to three times, cut R&D costs by up to 10x, and lower downstream failure risks by approximately 25%. These efficiencies are crucial for bringing new medicines to market more quickly and affordably.
Medvolt AI has rapidly gained traction since its operational launch. By early 2024, the startup had fully validated its platform and secured six global clients within five months. Its current 17-member team comprises experienced professionals in pharma, medtech, and AI. Notable clients include France-based SynBio Technologies, China’s Oda, and Indian firms E-Sync and Hi-Tech Biosciences.
Looking ahead, Medvolt AI is actively raising a $2 million seed round, having already secured Rs 3.2 crore in soft commitments. The company projects achieving $1 million in Annual Recurring Revenue (ARR) by 2027 through its platform services and plans to generate additional revenue by out-licensing its own developed drug assets. By 2028, Medvolt AI aims to establish a significant presence in the United States with over 50 clients and develop new drug assets for out-licensing, potentially unlocking multi-million-dollar deals in the global pharmaceutical market.
Also Read:
- AI in Drug Discovery and Development Market Poised for Significant Growth, Projected to Reach US$34.05 Billion by 2033
- Revolutionizing Healthcare: How Data Engineering and Generative AI Drive Efficiency and Enhance Patient Outcomes
Medvolt AI’s innovative contributions have not gone unnoticed. The company was selected as part of YourStory’s Tech30 cohort for 2025, recognizing it as one of India’s most promising startups. It has also been featured in the NASSCOM EMERGE 50 Compendium 2025 under the HealthTech category and has showcased its platform at prominent events such as Startup World Cup 2025, India Mobile Congress 2025, and Startup Mahakumbh 2025, highlighting its vision for transforming therapeutic innovation globally.
